Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915880 | 0.83 | ESR1 (0.35) | GABRA1GABRB2KDM4EGLAGAA | |
| SCHEMBL4915867 | 0.83 | TTR (0.31) | GABRA1GABRB2KDM4EGLAGAA | |
| SCHEMBL4915843 | 0.81 | — | — | |
| SCHEMBL4913038 | 0.81 | KDM4E (0.33) | KDM4EGLAGAA | |
| SCHEMBL4920699 | 0.81 | KDM4E (0.33) | KDM4EGLAGAA | |
| SCHEMBL4924347 | 0.80 | MCL1 (0.33) | KDM4EGLAGAA | |
| SCHEMBL4924242 | 0.80 | KDM4E (0.31) | KDM4EGLAGAA | |
| SCHEMBL4922195 | 0.78 | ATM (0.33) | — | |
| SCHEMBL4912696 | 0.78 | ESR1 (0.36) | — | |
| SCHEMBL4919556 | 0.77 | ESR2 (0.33) | GABRA1GABRB2KDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139824-A1 | DIBENZOTHIOPHENE OXIDE COMPOUND, AND PROCESS FOR PRODUCING THE SAME | SEKINE CHIZU | 2008-06-12 | — | — | US | disclosed |
| US-20070057229-A1 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | SEKINE CHIZU | 2007-03-15 | — | — | US | disclosed |
| US-7135579-B2 | Dibenzothiophene oxide compound, and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-11-14 | — | — | US | disclosed |
| US-6849202-B2 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-01 | — | — | US | disclosed |
| US-20040232384-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-11-25 | — | — | US | disclosed |
| US-20020110650-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070057229-A1 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | CCNT1, CCNA1, CCNT2 | CYP1A2 78/4885CYP3A4 77/4885CYP2C9 227/4885 |
| US-20040232384-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | CCNT1, BPNT1, PEAK1 | CYP1A2 427/4885CYP3A4 1193/4885CYP2C9 2364/4885 |
| US-20080139824-A1 | DIBENZOTHIOPHENE OXIDE COMPOUND, AND PROCESS FOR PRODUCING THE SAME | CCNT1, CCNA1, BPNT1 | CYP1A2 349/4885CYP3A4 347/4885CYP2C9 1289/4885 |
| US-20020110650-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | CCNT1, NAT1, PEAK1 | CYP1A2 611/4885CYP3A4 1203/4885CYP2C9 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.